AUGUST:
- Renalytix Clinical Advisory Board formed with world-leading, multi-disciplinary experts to support broadening adoption and use of FDA-authorized kidneyintelX.dkd.
JULY:
- 12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with type 2 diabetes and CKD.
